Cumberland Pharmaceuticals clinical trials we track

Check company identity source

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675 · Cumberland Pharmaceuticals

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events.

Check registry source
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675 · Cumberland Pharmaceuticals

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (safety & tolerability). After: Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 48 participants (planned). After: 46 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 6 Mar 2024.

Check registry source